2016
ARV-330: Androgen receptor PROTAC degrader for prostate cancer.
Neklesa T, Jin M, Crew A, Rossi A, Willard R, Dong H, Siu K, Wang J, Gordon D, Chen X, Ferraro C, Crews C, Coleman K, Winkler J. ARV-330: Androgen receptor PROTAC degrader for prostate cancer. Journal Of Clinical Oncology 2016, 34: 267-267. DOI: 10.1200/jco.2016.34.2_suppl.267.Peer-Reviewed Original ResearchAndrogen receptorAR mutationsProstate cancerTotal androgen receptorTreatment of miceAR protein levelsProstate cancer cellsGood pharmacokinetic propertiesPlasma PSAMetastatic diseaseNM R1881SC injectionAndrogen productionDisease progressionPSA expressionIntact miceTherapeutic effectCastrated miceVCaP cellsAnimal modelsProstate involutionTumor growthVivo efficacyPreclinical developmentPharmacokinetic properties
1996
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy
Wright G, Grob B, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer P, Moriarty R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996, 48: 326-334. PMID: 8753752, DOI: 10.1016/s0090-4295(96)00184-7.Peer-Reviewed Original ResearchConceptsProstate-specific membrane antigenAndrogen deprivation therapyExpression of PSMAProstate cancerLNCaP cellsAndrogen deprivationMetastatic specimensMembrane antigenCombination androgen deprivation therapyProstate-specific antigen expressionTissue specimensAntigen-positive tumor cellsHormone-independent prostate cancerPost-treatment specimenAndrogen deprivation treatmentAbsence of androgenPresence of testosteroneExtent of stainingWestern blot analysisAndrogen treatmentPSA expressionMetastatic tissuesPSMA expressionAntigen expressionProstate carcinoma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply